IDH1 and Cowden syndrome 1: Around 40–56% of CS have been reported to have mutations in isocitrate dehydrogenase (IDH) enzymes as an early event in disease development, causing the accumulation of the D-2-hydroxyglutarate (2-HG) oncometabolite [44,57], which prompted research on IDH inhibitors.